Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly is cutting the price of its popular weight-loss drug to compete with counterfeit weight-loss drugs. Zepbound will be sold for $399-$549 per month, compared to a previous list price of $1,059.

Eli Lilly just halved the price of its weight-loss drug — declaring war on the booming market of knock-offs

Eli Lilly is launching more supply of its weight loss drug Zepbound. The new single-dose vials will be priced lower than "all other incretin GLP-1 medicines for obesity.

Eli Lilly cuts cost of certain Zepbound doses by at least 50%

Its tirzepatide reduces the chance of developing diabetes, according to a new study. The population of people who might develop diabetes in the future is very large.

Eli Lilly's Stock Keeps Looking Better and Better. Here's the Latest Reason Why.

Eli Lilly has reduced the price of its weight loss drug by 50%, aiming to better meet the growing demand. Will it help?

Weight-loss drug Zepbound: Eli Lilly offers 50% discount on 2.5 mg and 5 mg vials to meet demand

Eli Lilly will offer weight-loss drug Zepbound in a new form at roughly half the list price. Eli Lilly stock edged higher.

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug

Abbott Labs

Bridger Aerospace Group Holdings Inc

Chevron

Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.

The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace

Hims & Hers Health

The new option is priced at a 50% or more discount compared to other weight-loss drugs.

Eli Lilly Is Offering a Cheaper Form of Zepbound. What It Means for Hims & Hers Stock.

Apple

Accenture Plc

Allegion

Applied Materials

Amphenol

Cintas Corp

D.R. Horton

Dick's Sporting Goods

Domino's Pizza

EOG Resources

Fastenal

FactSet Research Systems

Graco

Garmin

W.W. Grainger

HCA Healthcare

Home Depot

Hershey

Jack Henry & Associates

KLA-Tencor

Lincoln Electric Hlds

Lam Research

Mastercard

MarketAxess Holdings

The High Quality Dividend Stock Investable Universe is a rules-based approach to finding the best dividend stocks to invest in. The universe is made up of 50 stocks with a focus on identifying companies with strong growth metrics and proven to be winners in the past. A custom valuation model is applied to the investable universe to determine buy, hold or trim ratings for each stock.

50 High Quality Dividend Stocks To Own For The Long Term

Eli Lilly & Co. LLY, -0.23% said Tuesday patients can now access 2.5 mg and 5 mg single-dose vials of its weight-loss treatment Zepbound with an on-label prescription at a discount of at least 50% over other incretin medicines for obesity. The drug company said the vials are available through its LillyDirect self-pay channel.

Eli Lilly says patients can now access 2.5 mg and 5 mg vials of weight-loss drug Zepbound for at least 50% discount

Eli Lilly said it has begun selling single-dose vials of its popular weight-loss drug Zepbound in the U.S., aimed at patients who cannot get the cost of the medicine reimbursed through their health insurance plans.

Lilly launches single-dose vials of Zepbound for weight loss to expand US supply

Pfizer

Pfizer Inc. on Tuesday unveiled a new online platform designed to help simplify and coordinate healthcare for consumers, adding momentum to an emerging trend in big pharma that has drawn criticism from some provider groups and policy experts.

Pfizer follows Eli Lilly's lead in direct-to-consumer push

Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase access for patients without insurance coverage for the highly popular injection. The move also aims to expand the U.S. supply of Zepbound amid soaring demand and ensure patients are safely accessing the treatment as cheaper copycat versions of the drug gain traction.

Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply

Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity INDIANAPOLIS , Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand. The single-dose vials are priced at a 50% or greater discount compared to the list price of all other incretin (GLP-1) medicines for obesity.

Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity

Fortinet

Norwegian Cruise Line

Progressive

Top-ranked stocks Norwegian Cruise Line (NCLH), Eli Lilly (LLY), The Progressive (PGR) and Fortinet (FTNT) are likely to beat on earnings in their upcoming releases.

Buy 4 Top-Ranked Stocks to Play Likely Earnings Beat

Eli Lilly and Co. NYSE: LLY is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, known as Mounjaro for type 2 diabetes, and Zepbound for obesity. Its stock is trading back near its all-time high at $972.52.

Eli Lilly's Path to the Next Trillion Market Capitalization

Eli Lilly's crown jewel performed well in another pivotal clinical trial. The medicine's potential looks even more attractive than it already did.

Mounjaro Scores Yet Another Win: Why Eli Lilly Is Still a Buy

NVIDIA

Super Micro Computer

2024's best-performing S&P 500 stock so far should keep its top spot with a blow-out quarterly update this month. The No. 2 S&P 500 stock should continue to enjoy a massive tailwind throughout the rest of the year.

Prediction: These Will Be the Best-Performing S&P 500 Stocks of 2024

Eli Lilly's treatment for early Alzheimer's is expected to be blocked for use by Britain's National Health Service (NHS), The Telegraph reported on Friday.

Eli Lilly Alzheimer's drug to be blocked for use by NHS, The Telegraph reports

Novo Nordisk

Eli Lilly and Novo Nordisk's top diabetes drugs each brought in more than $3 billion in sales last quarter. Ozempic has been on the market for longer, but its growth rate isn't as impressive as that of other drugs.

These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk

INDIANAPOLIS , Aug. 22, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 5, 2024. Jacob Van Naarden, executive vice president and president, Lilly Oncology, will participate in a fireside chat at 7:45 a.m.

Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Eli Lilly's sales rose by 36% last quarter to $11.3 billion. The company's low cost of sales has boosted its bottom line at a much higher rate.

Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better

Johnson & Johnson

Eli Lilly's weight loss drugs are pushing the company's market cap toward $1 trillion. Johnson & Johnson is the global leader in drug sales, but its market cap is under $400 billion.

This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club

Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.

Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk

The rivalry between Novo Nordisk A/S NVO and Eli Lilly and Co LLY has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments.

Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle

Eli Lilly (LLY) shares set a record high on Tuesday after announcing that clinical trials of tirzepatide, the medicine used in the company's diabetes drug Mounjaro and injectable weight loss treatment Zepbound, significantly reduced the risk of developing type 2 diabetes in patients.

News for Eli Lilly Stock (LLY)